170 related articles for article (PubMed ID: 9427604)
1. Immunization for Ebola virus infection.
Xu L; Sanchez A; Yang Z; Zaki SR; Nabel EG; Nichol ST; Nabel GJ
Nat Med; 1998 Jan; 4(1):37-42. PubMed ID: 9427604
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.
Li W; Ye L; Carrion R; Mohan GS; Nunneley J; Staples H; Ticer A; Patterson JL; Compans RW; Yang C
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S398-403. PubMed ID: 25877553
[TBL] [Abstract][Full Text] [Related]
3. Identification of murine T-cell epitopes in Ebola virus nucleoprotein.
Simmons G; Lee A; Rennekamp AJ; Fan X; Bates P; Shen H
Virology; 2004 Jan; 318(1):224-30. PubMed ID: 14972550
[TBL] [Abstract][Full Text] [Related]
4. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS
Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337
[TBL] [Abstract][Full Text] [Related]
5. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells.
Rao M; Bray M; Alving CR; Jahrling P; Matyas GR
J Virol; 2002 Sep; 76(18):9176-85. PubMed ID: 12186901
[TBL] [Abstract][Full Text] [Related]
6. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein.
Wilson JA; Hart MK
J Virol; 2001 Mar; 75(6):2660-4. PubMed ID: 11222689
[TBL] [Abstract][Full Text] [Related]
7. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.
Pushko P; Bray M; Ludwig GV; Parker M; Schmaljohn A; Sanchez A; Jahrling PB; Smith JF
Vaccine; 2000 Aug; 19(1):142-53. PubMed ID: 10924796
[TBL] [Abstract][Full Text] [Related]
8. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.
Vanderzanden L; Bray M; Fuller D; Roberts T; Custer D; Spik K; Jahrling P; Huggins J; Schmaljohn A; Schmaljohn C
Virology; 1998 Jun; 246(1):134-44. PubMed ID: 9657001
[TBL] [Abstract][Full Text] [Related]
9. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.
Sullivan NJ; Geisbert TW; Geisbert JB; Xu L; Yang ZY; Roederer M; Koup RA; Jahrling PB; Nabel GJ
Nature; 2003 Aug; 424(6949):681-4. PubMed ID: 12904795
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs.
Mellquist-Riemenschneider JL; Garrison AR; Geisbert JB; Saikh KU; Heidebrink KD; Jahrling PB; Ulrich RG; Schmaljohn CS
Virus Res; 2003 Apr; 92(2):187-93. PubMed ID: 12686428
[TBL] [Abstract][Full Text] [Related]
11. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
12. Development of a preventive vaccine for Ebola virus infection in primates.
Sullivan NJ; Sanchez A; Rollin PE; Yang ZY; Nabel GJ
Nature; 2000 Nov; 408(6812):605-9. PubMed ID: 11117750
[TBL] [Abstract][Full Text] [Related]
13. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.
Feng Y; Li C; Hu P; Wang Q; Zheng X; Zhao Y; Shi Y; Yang S; Yi C; Feng Y; Wu C; Qu L; Xu W; Li Y; Sun C; Gao FG; Xia X; Feng L; Chen L
Emerg Microbes Infect; 2018 Jun; 7(1):101. PubMed ID: 29872043
[TBL] [Abstract][Full Text] [Related]
14. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
[TBL] [Abstract][Full Text] [Related]
15. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus.
Mohan GS; Li W; Ye L; Compans RW; Yang C
PLoS Pathog; 2012; 8(12):e1003065. PubMed ID: 23271969
[TBL] [Abstract][Full Text] [Related]
16. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.
Sullivan NJ; Geisbert TW; Geisbert JB; Shedlock DJ; Xu L; Lamoreaux L; Custers JH; Popernack PM; Yang ZY; Pau MG; Roederer M; Koup RA; Goudsmit J; Jahrling PB; Nabel GJ
PLoS Med; 2006 Jun; 3(6):e177. PubMed ID: 16683867
[TBL] [Abstract][Full Text] [Related]
17. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
Bukreyev A; Yang L; Zaki SR; Shieh WJ; Rollin PE; Murphy BR; Collins PL; Sanchez A
J Virol; 2006 Mar; 80(5):2267-79. PubMed ID: 16474134
[TBL] [Abstract][Full Text] [Related]
18. Protective efficacy of neutralizing antibodies against Ebola virus infection.
Takada A; Ebihara H; Jones S; Feldmann H; Kawaoka Y
Vaccine; 2007 Jan; 25(6):993-9. PubMed ID: 17055127
[TBL] [Abstract][Full Text] [Related]
19. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.
Warfield KL; Olinger G; Deal EM; Swenson DL; Bailey M; Negley DL; Hart MK; Bavari S
J Immunol; 2005 Jul; 175(2):1184-91. PubMed ID: 16002721
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel HLA-A11-restricted T-cell epitopes in the Ebola virus nucleoprotein.
Li D; Li P; Song N; Jiang Y; Zeng Y; Zhao G; Fa Y; Ye H; Lone Y; Zhou Y; Sun S; Zeng L
Microbes Infect; 2019; 21(1):56-62. PubMed ID: 29775667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
